Hematology / Oncology
AML and MDS trajectories across cytopenias, blasts, transfusion dependence. The trends that matter for treatment decisions, visible at a glance.
CBC w/ DiffBlasts %ReticulocytesTransfusion log
TrendHUD makes care faster, more accurate, and more convenient — without adding work for the physician.
Reviewing a year of CBCs in Epic means dozens of clicks across dozens of result panels. TrendHUD ingests every LOINC-coded lab from your EHR export and renders the whole trajectory on one screen — correlations without the click-storm.
Correlations without the click-stormOne canvas. Three waypoints. Drop the file, fly forward.
Epic, NextGen, InteliChart — drop the file, we parse it.
Normal-range bands rendered as translucent green planes so abnormal values pop.
Surfaces the data of clinical interest — and proposes the next step, grounded in the patient's own trajectory.
An 18-month IDH1-mutated AML chart. Toggle metrics in the sidebar. Hover the timeline to crosshair every panel at once.
Hit the blue brain to see the AI agent.
Real product UI. Mock patient (de-identified). Every line, every band, every cycle marker is exactly what a TrendHUD physician sees.
Click Interpret and the agent reads your patient's longitudinal record the way a colleague would — pointing to the trends worth your attention, citing the dates that support them, and proposing the next move grounded in your own protocol.
Ranks abnormal trends by clinical significance, not row order. The dip in your ANC before the next cycle gets surfaced — not the in-range RDW.
Every observation points back to the data points and source dates that triggered it. Click a citation, jump to the timepoint.
Fine-tuned on AGILE, IDH-inhibitor, hypomethylating-agent, and standard 7+3 induction protocols. Proposals come grounded in the regimen the patient is already on.
The agent suggests. Nothing routes anywhere without your signature. Every recommendation is a draft, not a directive.
ANC has held above the 1.0 K/µL AGILE threshold for 6 consecutive draws (3/3, 3/17, 3/24, 3/31, 4/14, 4/28). However, PLT 67 K/µL and HGB 8.3 g/dL remain below criteria — formal CR will need bone-marrow blast confirmation.
HGB shows a −1.8 g/dL drift since C7 start (Feb 1) despite ongoing Aranesp support (3 doses since 2/16). Pattern matches treatment-related cytopenia rather than disease progression.
Consider scheduling BM biopsy alongside the C10 plan window (week of 5/19) to capture blast % for AGILE CR confirmation. Continue Ivosidenib at current dose; defer Olutasidenib transition pending biopsy.
What did blasts trend look like vs the 7+3 cohort?
TrendHUD's longitudinal canvas is configured per specialty out of the box. The metrics that matter, ordered the way you read.
AML and MDS trajectories across cytopenias, blasts, transfusion dependence. The trends that matter for treatment decisions, visible at a glance.
A1C, TSH, free T4, B12, vitamin D — every endocrine panel on a single longitudinal canvas. Spot drift before the patient does.
Pre-op labs, intra-op flowsheet values, post-op recovery markers — one continuous chart instead of three siloed systems.
FHIR for ingestion, LOINC for normalization, BAA on the enterprise tier. No new vocabulary. No proprietary lock-in.
Reads US Core R4 Observation, DiagnosticReport, Encounter resources straight from your EHR export.
Every metric mapped to its LOINC code at ingestion. Cross-EHR comparisons stop being a chart-review project.
Pilot deployments use de-identified exports. Enterprise tier ships with executed BAA and audit logging.
Heme/onc, endocrinology, and plastic surgery are first in line. Tell us your panel mix and we'll get you on a call this week.